Second study shows that octreotide may prevent early rebleeding in cirrhosis

BMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7140.1320 (Published 25 April 1998) Cite this as: BMJ 1998;316:1320
  1. Gennaro D'Amico, Consultant in gastroenterology,
  2. Flavia Politi, Research fellow,
  3. Adele D'Antoni, Research fellow,
  4. Gandolfo Giannuoli, Senior registrar,
  5. Linda Pasta, Consultant in gastroenterology,
  6. Giovanni Vizziani, Senior registrar,
  7. Mario Traina, Senior registrar,
  8. Alberto Morabito, Associate professor of medical statistics,
  9. Luigi Pagliaro, Full professor of medicine
  1. Divisione di Medicina, Ospedale V Cervello, 90146 Palermo, Italy

    EDITOR—Jenkins et al have reported a randomised trial showing that long term subcutaneous octreotide together with sclerotherapy significantly reduces the risk of recurrent bleeding from oesophageal varices in liver cirrhosis.1

    In a double blind placebo controlled pragmatic trial we have found that a 15 day course of subcutaneous octreotide was effective in preventing early rebleeding in cirrhosis. After acute bleeding of the upper digestive tract had been controlled, 262 consecutive patients with cirrhosis were randomised to receive octreotide 100 μg subcutaneously three times a day for 15 days (n=131) or …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription